Comment on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial

Pierluigi Carratù; Silvano Dragonieri; Onofrio Resta

doi:10.4414/smw.2019.20132

Technical comment

Vol. 149 No. 3940 (2019)

Comment on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial

Pierluigi Carratù
Silvano Dragonieri
Onofrio Resta

DOI: https://doi.org/10.4414/smw.2019.20132
Cite this as:: Swiss Med Wkly. 2019;149:w20132
Published: 30.09.2019

References

Hostettler K, Baty F, Kleiner R, Junker L, Tamm M, Brutsche M. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial. Swiss Med Wkly. 2018;148:w14677. doi:.https://doi.org/10.4414/smw.2018.14677
Sofia M, Mormile M, Faraone S, Alifano M, Carratù P, Carratù L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis. 1995;12(2):118–23.

Publication image

How to Cite

1.

Carratù P, Dragonieri S, Resta O. Comment on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial. Swiss Med Wkly [Internet]. 2019 Sep. 30 [cited 2024 Nov. 26];149(3940):w20132. Available from: https://smw.ch/index.php/smw/article/view/2678

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

[1] Hostettler K, Baty F, Kleiner R, Junker L, Tamm M, Brutsche M. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial. Swiss Med Wkly. 2018;148:w14677. doi:.https://doi.org/10.4414/smw.2018.14677

[2] Sofia M, Mormile M, Faraone S, Alifano M, Carratù P, Carratù L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis. 1995;12(2):118–23.